TFRC and myeloid sarcoma: In contrast, DFP treatment significantly decreased Fe2+ levels in optic nerve tissue, downregulated TFR1 and Iba-1 expression, and inhibited iron deposition, ferroptosis, microglial activation, and astrocyte proliferation, thereby reducing myelin loss and optic nerve damage in MS mice (Rayatpour et al., 2022).